2Lehmann M, Vilar Kde S, Franco A, et al. Activity of topoisomerase inhibitors daunorubicin, idarubicin, and aclarubicin in the Drosophila Somatic Mutation and Recombination Test [J]. Environ Mol Mutagen, 2004, 43(4) : 250-257.
3Avvisati G, Petti MC, Lo-Coco F, et al. Induction therapy with idarubicin alone significantly influences event-free survival duration in patients with newly diagnosed hypergranular acute promyelocytic leukemia : final results of the GIMEMA randomized study LAP 0389 with 7 years of minimal follow-up [ J ] . Blood, 2002, 100(9) : 3141-3146.
